Systematic Review of Oral Janus Kinase Inhibitors in Alopecia Areata: Insights from 2020 to 2025 Studies

    December 2025 in “ International Journal of Innovative Technologies in Social Science ”
    Anna Mandecka, Kornela Kotucha-Cyl, Weronika Komala … Marta Nowocień
    Studysummary This systematic review concluded that oral JAK inhibitors, such as baricitinib and deuruxolitinib, are effective and generally well-tolerated treatments for moderate-to-severe alopecia areata, offering advantages over traditional therapies.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Read the full study on rsglobal.pl →
    Discuss this study in the Community →

    Research cited in this study 24

    1. Local Corticosteroids for Alopecia Areata: A Narrative Review Dermatology and Therapy · 2025
    2. Comparison of Efficacy of Baricitinib Versus Methotrexate Therapy in the Treatment of Severe Alopecia Areata 2025
    3. The Relative Efficacy and Safety of Monotherapies for Alopecia Areata: A Network Meta-Analysis Study Journal of Cosmetic Dermatology · 2025
    4. Alopecia Areata: Understanding the Pathophysiology and Advancements in Treatment Modalities Cureus · 2025
    5. Baricitinib for the Treatment of Severe Alopecia Areata: Results from a 52-Week Multicenter Retrospective Real-World Study Journal of Dermatological Treatment · 2025
    6. Comparative Efficacy and Safety of Baricitinib Against Traditional Therapies in Severe Alopecia Areata: A Retrospective Cohort Study Journal of Cosmetic Dermatology · 2024
    7. Efficacy and Safety of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, in Adolescent and Adult Patients with Alopecia Totalis and Alopecia Universalis The Journal of Dermatology · 2024
    8. Efficacy and Safety of Deuruxolitinib, an Oral Selective Janus Kinase Inhibitor, in Adults with Alopecia Areata: Results from the Phase 3 Randomized, Controlled Trial (THRIVE-AA1) Journal of the American Academy of Dermatology · 2024
    9. Long-Term Efficacy and Safety of Baricitinib in Patients With Severe Alopecia Areata: 104-Week Results From BRAVE-AA1 and BRAVE-AA2 Journal of the European Academy of Dermatology and Venereology · 2024
    10. Gut Microbiome, Metabolome and Alopecia Areata Frontiers in microbiology · 2023
    11. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata Over 52 Weeks in Phase III Trials American Journal of Clinical Dermatology · 2023
    12. Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-Analysis Acta dermato-venereologica · 2023
    13. Alopecia Areata: Diagnostic and Therapeutic Recommendations of the Polish Society of Dermatology. Part 2: Treatment Przegląd Dermatologiczny · 2023
    14. Alopecia Areata: Diagnostic and Therapeutic Recommendations of the Polish Dermatological Society, Part 1: Diagnosis and Severity Assessment Przegla̧d dermatologiczny · 2023
    15. How Our Microbiome Influences the Pathogenesis of Alopecia Areata Genes · 2022
    16. An Overview of JAK/STAT Pathways and JAK Inhibition in Alopecia Areata Frontiers in immunology · 2022
    17. Alopecia Areata: An Update on Etiopathogenesis, Diagnosis, and Management Clinical Reviews in Allergy & Immunology · 2021
    18. A Phase 2a Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of the Oral Janus Kinase Inhibitors Ritlecitinib and Brepocitinib in Alopecia Areata: 24-Week Results Journal of the American Academy of Dermatology · 2021
    19. Alopecia Areata: A Review on Diagnosis, Immunological Etiopathogenesis, and Treatment Options Clinical and Experimental Medicine · 2021
    20. Emerging Topical and Systemic JAK Inhibitors in Dermatology Frontiers in Immunology · 2019
    21. Janus Kinase Inhibitors: An Innovative Treatment for Alopecia Areata Journal of dermatology · 2019
    22. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study Dermatology · 2018
    23. Treatment of Alopecia Universalis with Topical Janus Kinase Inhibitors – A Double Blind, Placebo, and Active Controlled Pilot Study International Journal of Dermatology · 2018
    24. Alopecia Areata: Overview and Insights from January 2018 Journal of The American Academy of Dermatology · 2017